Buprenorphine Treatment Centers in Nebraska

Yes. Providers in Nebraska must document a current OUD diagnosis to prescribe buprenorphine as part of medication-assisted treatment. The intake assessment typically takes 60–90 minutes and includes a physical exam, drug screen, and psychiatric history — results are used to confirm eligibility.

Free buprenorphine treatment is possible in Nebraska for patients who qualify for Nebraska Medicaid (Heritage Health), are enrolled in State Opioid Response–funded clinics, or use charity-care programs at community behavioral-health centers. Call 988 or 1-800-662-4357 for live referrals.

Yes. Nebraska Medicaid (Heritage Health) covers Sublocade and Vivitrol as part of the MAT benefit; most plans require prior authorization documenting prior MAT adherence. Billing is handled by the Nebraska provider as a medical (not pharmacy) benefit.

Yes. Medicare Part B covers methadone through enrolled Opioid Treatment Programs and Part D covers buprenorphine and naltrexone prescriptions. Medicare Advantage plans in Nebraska include the same MAT benefits under the integrated plan structure.

Clinics maintain a confidential medical record covering diagnosis, treatment plan, drug screens, counseling notes, and dose history. Records are protected by 42 CFR Part 2 — stricter than HIPAA — and cannot be released without your written consent or a specific court order.

No. There is no legal or clinical cap on how long you can remain on buprenorphine in Nebraska. Insurance must continue to cover MAT as long as the prescribing clinician documents medical necessity.

For methadone and buprenorphine, continued opioid use at entry is expected — the medication is designed to stop use safely. For naltrexone, 7–14 opioid-free days are required first. Your Nebraska clinician will confirm the correct induction strategy at intake.

Yes. Records are protected by 42 CFR Part 2, which is stricter than HIPAA. Your employer, family, or law enforcement cannot access your records without your specific written consent or a narrowly tailored court order. Confidentiality applies from the first visit onward.

Buprenorphine and methadone do not test positive on standard 5-panel drug tests — specialty panels are needed. Naltrexone and its metabolites are not screened on standard panels. Share an MAT provider letter with any employer or court drug-testing program to avoid confusion.

Yes. Methadone and buprenorphine are the evidence-based standard of care in pregnancy, endorsed by ACOG and SAMHSA. Staying on MAT protects both mother and fetus; unmedicated withdrawal is riskier than continued MAT. Nebraska providers coordinate care with obstetrics.

No. Attending 12-step programs is optional; SMART Recovery, Women for Sobriety, Refuge Recovery, and secular support groups are all acceptable alternatives. Nebraska MAT clinicians can help you match with a peer group aligned to your values.

Yes, with proper documentation. Bring a letter from your Nebraska MAT prescriber, medication in its original pharmacy container, and check destination-country rules — some countries restrict methadone and buprenorphine. The International Narcotics Control Board maintains destination-country guidance.